Literature DB >> 7522643

Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor.

G E Tjønnfjord1, R Steen, S A Evensen, E Thorsby, T Egeland.   

Abstract

Primed peripheral blood hematopoietic stem cells (PBSC) generate and sustain lymphohematopoiesis in myeloablated animals, and recent reports indicate that allogeneic transplantation using PBSC grafts may be feasible in humans. A major concern with the use of PBSC transplants is that permanent engraftment may be limited because of lack of sufficient numbers of primitive progenitor cells in the graft. In the present study, in vitro colony formation and immunophenotype of CD34+ cells in PB of healthy adults during short-term granulocyte colony-stimulating factor (G-CSF) administration were compared with that of CD34+ cells in normal bone marrow (BM). The number of CD34+ cells mobilized to PB peaked at day 4 or 5 of G-CSF administration. The phenotypic profile of CD34+ PB cells showed a substantial increase in the percentage of CD34+CD13+ and CD34+CD33+ cells (myeloid progenitors) and a corresponding decrease in the percentage of CD34+CD10+ and CD34+CD19+ cells (B lymphoid progenitors) compared with CD34+ BM cells. The other subsets studied, including CD34+CD38- and CD34+HLA-DR- cells, were present in both compartments in similar proportions. Furthermore, primed CD34+ PB cells were enriched for colony-forming cells (CFC) and displayed an increased clonogenicity when compared with their counterparts in BM. A comparison between a postulated PBSC graft and an average BM graft is presented, showing that such PBSC grafts will be enriched for CD34+ cells as a whole, CD34+CD33+ cells, and colony-forming cells (CFC), factors which have been shown to correlate to acceleration of hematologic reconstitution and reduction in requirements for supportive care in autografting. Hence, we predict that allogeneic transplantation using G-CSF-primed PBSC grafts will result in a more rapid hematologic reconstitution after myeloablative conditioning than BM grafting. The question of whether PBSC allografting will result in permanent engraftment and clinical benefits as observed in autografting has to be determined in prospective clinical studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

Review 2.  Autologous peripheral blood stem cells: collection and processing.

Authors:  M Hansson; A Svensson; P Engervall
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

3.  The role of plasma granulocyte colony stimulating factor and bone marrow dysfunction after severe trauma.

Authors:  Kristin M Cook; Ziad C Sifri; Gregg M Baranski; Alicia M Mohr; David H Livingston
Journal:  J Am Coll Surg       Date:  2012-10-10       Impact factor: 6.113

4.  Quality assessment of cellular therapies: the emerging role of molecular assays.

Authors:  David F Stroncek; Ping Jin; Jiaqiang Ren; Ji Feng; Luciano Castiello; Sara Civini; Ena Wang; Francesco M Marincola; Marianna Sabatino
Journal:  Korean J Hematol       Date:  2010-03-31

Review 5.  Clinical application of allogeneic peripheral blood stem cells transplantation.

Authors:  J Tanaka; M Kasai; M Imamura; M Asaka
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

6.  Prediction model for CD34 positive cell yield in peripheral blood stem cell collection on the fourth day after G-CSF administration in healthy donors.

Authors:  Tetsuichi Yoshizato; Naoko Watanabe-Okochi; Yasuhito Nannya; Motoshi Ichikawa; Tsuyoshi Takahashi; Tomohiko Sato; Akiko Masuda; Yutaka Yatomi; Nelson Hirokazu Tsuno; Mineo Kurokawa; Koki Takahashi
Journal:  Int J Hematol       Date:  2013-05-22       Impact factor: 2.490

7.  CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.

Authors:  Elisabet Björklund; Astrid Gruber; Joanna Mazur; Anna Mårtensson; Mona Hansson; Anna Porwit
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

8.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; John P Miller; Brent R Logan; Roberta J King; J Douglas Rizzo; Susan F Leitman; Paolo Anderlini; Michael D Haagenson; Seira Kurian; John P Klein; Mary M Horowitz; Dennis L Confer
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

9.  Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.

Authors:  D Wisniewski; M Affer; J Willshire; B Clarkson
Journal:  Blood Cancer J       Date:  2011-09-30       Impact factor: 11.037

10.  Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients.

Authors:  Emanuela Anna Roselli; Riccardo Mezzadra; Marta Claudia Frittoli; Giulietta Maruggi; Erika Biral; Fulvio Mavilio; Fabrizio Mastropietro; Antonio Amato; Giovanni Tonon; Chiara Refaldi; Maria Domenica Cappellini; Marco Andreani; Guido Lucarelli; Maria Grazia Roncarolo; Sarah Marktel; Giuliana Ferrari
Journal:  EMBO Mol Med       Date:  2010-08       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.